AI GENERATED
### 1. Vertex Pharmaceuticals
- Leading programs: VX-880 / VX-264
- Uses stem-cell–derived insulin-producing beta cells
- Some patients achieved insulin independence in trials
- Challenge: immunosuppression often still required
- Most advanced clinical results today
### 2. Sana Biotechnology
- Developing “hypoimmune” (immune-evasive) cell therapies
- Goal: transplant beta cells without immune suppression
- Early human data shows insulin production potential
- Still early-stage but highly promising
### 3. CRISPR Therapeutics
- Gene-edited stem-cell approaches for diabetes
- Focus on immune-protected beta cell replacement
- Early clinical trials in progress
- Strong gene-editing platform advantage
### 4. ViaCyte (now part of Vertex ecosystem)
- Pioneer in stem-cell derived pancreatic progenitors
- Developed implantable devices for beta cells
## Are cell-replacement diabetes therapies still only in animals?
### Short answer
No — they are **not only in animal studies anymore**.
The field has moved into **early human clinical trials**, but it is still experimental.
---
## Where the research actually is
### ❌ Not just animal studies
Many of these therapies have already passed:
- Lab (cell culture) testing
- Animal testing (mouse, primate studies)
But that is not where the leading edge is anymore.
## ✔ Human trials are already happening
### Vertex Pharmaceuticals (VX-880)
- Stem-cell–derived insulin-producing cells
- Tested in **real human patients**
- Some patients showed:
- restored insulin production
- improved blood sugar control
- partial or full insulin independence in trials
- Still requires immunosuppressive drugs